Beijing, China-based TargetingOne has raised RMB100 million ($14 million) in a new round of financing from Beijing Pharmaceutical and Health Industry Investment Fund for the development and commercialisation of its core products, digital PCR systems and point-of-care testing products.

Founded in 2015, TargetingOne has developed hundreds of reagents based on its proprietary digital PCR technology, covering the fields of oncology, pathogens and eugenics. Just two months ago, TargetingOne closed nearly RMB 100 million ($14 million) in Series B+ financing led by Shengdi Investment, Lilly Asia Ventures and Jiuzhi Capital.

The Beijing Pharmaceutical and Health Industry Investment Fund is a government investment fund in the medical and health industry established by the Beijing Municipal Government at the end of 2023, focusing on key industry sectors such as innovative drugs, innovative medical devices, cell and gene therapy, and digital health.

en_GBEnglish (UK)